Skip to main content
. 2020 Sep 23;10:15530. doi: 10.1038/s41598-020-72661-9

Figure 3.

Figure 3

Epigenomic screening, validation and re-validation of response marker for HER2-positive breast cancers. (A) Workflow of the screening by DNA methylation analysis of the screening set, including 14 samples with pCR and 20 samples with non-pCR. Details are explained in the text. (B) Methylation levels of 6 genes measured by pyrosequencing in the validation set. Differential methylation of only HSD17B4 was validated (P = 0.003). (C) Methylation levels of HSD17B4 in the re-validation set. Differential methylation of HSD17B4 was re-validated (P = 0.0007).